Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03244826 · ClinicalTrials.gov registry record · NA
Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 404
- Enrollment target
NCT03244826 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 404 participants.
The verdict
NCT03244826, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 404 participants
- Enrollment target
Study Summary
This research study aims to evaluate the effectiveness of allowing patients who have had a hematopoietic cell transplant to receive some of their post-transplant care with a local oncologist rather than returning to the transplant center for all of their follow-up.
Interventions
- OTHER Standard Care
- OTHER Shared Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2022-08-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03244826
The ClinicalTrials.gov registry entry for NCT03244826 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.
NCT03244826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03244826 about?
NCT03244826 is a clinical study titled "Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation". This research study aims to evaluate the effectiveness of allowing patients who have had a hematopoietic cell transplant to receive some of their post-transplant care with a local oncologist rather than returning to the transplant center for all of their follow-up.
What is the current status of trial NCT03244826?
This trial is currently completed. It is a NA study. The enrollment target is 404 participants. The study started on 2018-01-01. Estimated completion is 2022-08-22.
What interventions are being tested in trial NCT03244826?
The interventions under investigation include: Standard Care (OTHER), Shared Care (OTHER).
Who is sponsoring clinical trial NCT03244826?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.